证券日报网讯 12月3日，东富龙在互动平台回答投资者提问时表示，公司在定期报告中披露股东总数。 （文章来源：证券日报） ...

消息面上，安科生物近期披露合作进展，与维昇药业合作的隆培促生长素即将获批。据悉，7月14日， 安科生物宣布，公司与维昇药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及。 智通财经获悉，维昇药业-B(02561)再涨超12%，截至发稿，涨7.11%，报35.26港元，成交额190.82万港 元。 值得注意的是，11月6日，第八届进博会期间，维昇药业与国内制药装备龙头企业东富龙达成双腔冻干 制剂技术战略合作，并与临港新片区管委会、临港集团物贸平台签署产业协同协议，标志着其在"全球 创新、中国加速"的战略实践进一步落地。 本文源自：智通财经网 ...

消息面上，安科生物近期披露合作进展，与维昇药业合作的隆培促生长素即将获批。据悉，7月14日， 安科生物宣布，公司与维昇药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及。 值得注意的是，11月6日，第八届进博会期间，维昇药业与国内制药装备龙头企业东富龙达成双腔冻干 制剂技术战略合作，并与临港新片区管委会、临港集团物贸平台签署产业协同协议，标志着其在"全球 创新、中国加速"的战略实践进一步落地。 智通财经APP获悉，维昇药业-B(02561)再涨超12%，截至发稿，涨7.11%，报35.26港元，成交额190.82 万港元。 ...

11月20日，东富龙盘中下跌2.01%，截至09:52，报16.55元/股，成交6441.71万元，换手率0.68%，总市 值126.74亿元。 分红方面，东富龙A股上市后累计派现17.82亿元。近三年，累计派现5.12亿元。 资金流向方面，主力资金净流出884.64万元，特大单买入0.00元，占比0.00%，卖出112.90万元，占比 1.75%；大单买入589.15万元，占比9.15%，卖出1360.89万元，占比21.13%。 东富龙今年以来股价涨25.62%，近5个交易日跌2.76%，近20日涨11.75%，近60日涨9.53%。 资料显示，东富龙科技集团股份有限公司位于上海市闵行区都会路1509号，成立日期1993年12月25日， 上市日期2011年2月1日，公司主营业务涉及医用冻干机及冻干系统的研发、设计、生产、销售和服务。 主营业务收入构成为：制剂事业部44.92%，生物工艺事业部29.83%，工程事业部9.19%，食品事业部 9.16%，售后服务与配件6.81%，其他(补充)0.09%。 东富龙所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、基因测序、生 物制造、合成 ...

截至9月30日，东富龙股东户数3.14万，较上期减少2.14%；人均流通股17910股，较上期增加2.19%。 2025年1月-9月，东富龙实现营业收入37.04亿元，同比增长6.14%；归母净利润1.32亿元，同比减少 13.86%。 分红方面，东富龙A股上市后累计派现17.82亿元。近三年，累计派现5.12亿元。 11月17日，东富龙跌1.87%，成交额4.37亿元。两融数据显示，当日东富龙获融资买入额4971.01万元， 融资偿还4592.23万元，融资净买入378.77万元。截至11月17日，东富龙融资融券余额合计3.01亿元。 融资方面，东富龙当日融资买入4971.01万元。当前融资余额3.00亿元，占流通市值的2.19%，融资余额 超过近一年70%分位水平，处于较高位。 融券方面，东富龙11月17日融券偿还1.76万股，融券卖出1.10万股，按当日收盘价计算，卖出金额19.65 万元；融券余量5.80万股，融券余额103.59万元，超过近一年90%分位水平，处于高位。 资料显示，东富龙科技集团股份有限公司位于上海市闵行区都会路1509号，成立日期1993年12月25日， 上市日期2011年2月1日 ...

Group 1 - The core point of the news is the performance and market position of Dongfulong Technology Group Co., Ltd., which saw a stock price increase of 5.11% to 17.89 CNY per share, with a total market capitalization of 13.701 billion CNY [1] - Dongfulong's main business involves the research, design, production, sales, and service of medical freeze-dryers and freeze-drying systems, with revenue contributions from various segments: 44.92% from the formulation division, 29.83% from the bioprocess division, 9.19% from the engineering division, 9.16% from the food division, 6.81% from after-sales service and parts, and 0.09% from others [1] Group 2 - According to data, Jin Xin Fund has a significant holding in Dongfulong, with its Jin Xin Shenzhen Growth Mixed A Fund increasing its stake by 156,300 shares in the third quarter, bringing the total to 2.3408 million shares, which represents 3.38% of the fund's net value [2] - The Jin Xin Shenzhen Growth Mixed A Fund has achieved a year-to-date return of 53.8%, ranking 873 out of 8140 in its category, and a one-year return of 40.89%, ranking 1139 out of 8056 [2] Group 3 - The fund managers of Jin Xin Shenzhen Growth Mixed A are Huang Biao and Yang Chao, with Huang having a tenure of 4 years and 176 days and a best return of 119.15% during his management period [3] - Yang Chao has a tenure of 4 years and 189 days, with a best return of 76.11% during his management period [3]

Core Viewpoint - Dongfulong's stock price has shown a significant increase of 29.49% year-to-date, despite a slight decline of 0.18% in the last five trading days, indicating a volatile but generally positive market performance [1][2]. Financial Performance - For the period from January to September 2025, Dongfulong achieved a revenue of 3.704 billion yuan, reflecting a year-on-year growth of 6.14%. However, the net profit attributable to shareholders decreased by 13.86% to 132 million yuan [2]. - Cumulative cash dividends since the A-share listing amount to 1.782 billion yuan, with 512 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 2.14% to 31,400, while the average circulating shares per person increased by 2.19% to 17,910 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 888,200 shares to 8.2218 million shares, and Southern CSI 1000 ETF, which reduced its holdings by 48,600 shares to 3.5016 million shares [3]. Market Activity - On November 13, Dongfulong's stock rose by 2.03% to 17.06 yuan per share, with a trading volume of 49.4883 million yuan and a turnover rate of 0.52%. The total market capitalization stands at 13.065 billion yuan [1]. - The net inflow of main funds was 2.2165 million yuan, with large orders accounting for 18.00% of purchases and 13.52% of sales [1]. Business Overview - Dongfulong Technology Group Co., Ltd. specializes in the research, design, production, sales, and service of medical freeze-dry machines and systems. The revenue breakdown shows that the formulation division contributes 44.92%, the bioprocess division 29.83%, the engineering division 9.19%, the food division 9.16%, and after-sales service and parts 6.81% [1]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices [1].

Core Insights - The Ministry of Industry and Information Technology (MIIT) of China has released two significant documents regarding the development of biological manufacturing, focusing on high-performance bioreactors and pilot-scale platforms, which aim to advance this emerging productive force in the industry [2][11]. Summary by Sections High-Performance Bioreactors - On November 4, MIIT published a notice listing the selected units for the innovation tasks related to high-performance bioreactors, with 9 key bioreactors and 23 leading universities, research institutes, and enterprises included in the list [2][4]. - Notable participants include companies and institutions such as Womei Biotech, the Chinese Academy of Sciences Tianjin Institute of Industrial Biotechnology, and East China University of Science and Technology [2][5]. Pilot-Scale Platforms - On November 10, MIIT announced the first batch of units selected for the biological manufacturing pilot-scale capability construction platform, comprising 43 units [2][8]. - Among these, 12 units received ratings of four stars or above, including Tianjin University Frontier Research Institute of Synthetic Biology and Beijing University of Chemical Technology Qinhuangdao Bohai Biological Industry Research Institute [3][9]. Key Participants - The list of selected units for high-performance bioreactors includes various leading organizations such as: - Womei Biotech - East China University of Science and Technology - Dibeier Biotechnology - Chutian Technology [5][6]. - The pilot-scale platform includes institutions like: - Beijing Zhaoyan Biotechnology Co., Ltd. - Tianjin University - Chinese Academy of Sciences Tianjin Institute of Industrial Biotechnology [9][10].

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

Core Insights - Weisheng Pharmaceutical made its debut as an exhibitor at the China International Import Expo, signing two significant agreements focused on strategic cooperation in dual-chamber freeze-dried formulation technology and industrial collaboration with local authorities [1][6]. Group 1: Strategic Partnerships - The collaboration with Dongfulong aims to address the industry pain points of stability and ease of use in high-end biological formulations through dual-chamber freeze-dried technology [2][5]. - Weisheng's core product, Lonapegsomatropin, will utilize this technology, allowing for stable storage at room temperature for up to six months without preservatives [2][3]. Group 2: Product Development and Market Entry - The application for Lonapegsomatropin's market approval is expected to be accepted by the National Medical Products Administration in March 2024, with a projected approval by the end of 2025 [3]. - The partnership with Dongfulong is intended to ensure quality control throughout the entire process from research and development to commercialization [3][5]. Group 3: Local Development and Ecosystem - Weisheng Pharmaceutical is recognized as a key innovative biopharmaceutical company in the Lingang New Area, focusing on endocrine-related treatments and has rapidly grown since its establishment in 2022 [6]. - The agreements with the Lingang New Area Management Committee and Lingang Group aim to deepen industrial collaboration and enhance the local ecosystem for biopharmaceuticals [6][9].